Arvinas price target raised to $16 from $14 at Piper Sandler

Piper Sandler raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps an Overweight rating on the shares. ARV-102 is an oral, CNS-penetrant LRRK2 degrader in development for Parkinson’s Disease and Progressive Supranuclear Palsy. Arvinas presented Phase I data showing ARV-102 achieved LRRK2 degradation of 50%-75% in CSF of healthy volunteers and up to 97% in plasma of Parkinson’s patients, the firm notes. Arvinas plans to initiate a Phase Ib study in PSP in the first half of 2026. Arvinas and Pfizer (PFE) agreed to jointly out-license vepdegestrant, which has a June 5, 2026, PDUFA date in ESR1-mutant metastatic breast cancer.